Annals On Call Podcast Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes
Aug 18, 2025
Join Dr. Centor as he speaks with Kevin Kip, VP for Clinical Analytics at the University of Pittsburgh, and Anum Saeed, Assistant Professor of Cardiology at UPMC. They delve into the intriguing study comparing semaglutide and empagliflozin for type 2 diabetes, highlighting critical outcomes such as mortality and cardiovascular events. They break down complex topics like emulating clinical trials using electronic health records and discuss how demographic factors influence treatment adherence. Their insights pave the way for future diabetes treatment strategies.
AI Snips
Chapters
Transcript
Episode notes
Target-Trial Emulation From EHRs
- The study emulated randomized trials using EHR data and careful propensity matching to approximate random assignment.
- This approach lets researchers compare real-world outcomes between semaglutide, dulaglutide, and empagliflozin without running new RCTs.
How The Cohort Was Selected
- Include only patients newly prescribed one study drug with a prior washout period and apply standard clinical-trial exclusions.
- Match on key features and disallow prior concurrent GLP-1 and SGLT-2 use to maintain clear treatment groups.
Primary Outcome And Follow-Up
- The primary composite outcome was all-cause death, myocardial infarction, or stroke with median follow-up ~2.2 years.
- Secondary analyses separated components, focusing on MI and stroke as hard cardiovascular endpoints.